NCT06251388View on ClinicalTrials.gov

A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

October 1, 2026

Conditions
Cervical Cancer
Interventions
DRUG

AK104

AK104（10.0 mg/kg，intravenous (IV) infusion，Q3W）maintained with no more than 1 year.

Trial Locations (1)

610041

RECRUITING

West China Second University Hospital, Chengdu

All Listed Sponsors
collaborator

Affiliated Hospital of North Sichuan Medical College

OTHER

collaborator

The Affiliated Hospital Of Southwest Medical University

OTHER

lead

West China Second University Hospital

OTHER